Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

The typical biotech playbook is straightforward but risky: Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new drug ...